Mesothelioma

Avenge Bio Announces Successful Completion of First Dose Level Cohort in Phase 1/2 Clinical Trial of AVB-001 for the Treatment of Ovarian Cancer

Retrieved on: 
Wednesday, April 26, 2023

and QUINCY, Mass., April 26, 2023 /PRNewswire/ -- Avenge Bio, Inc. ("Avenge"), a clinical stage, oncology-focused biotechnology company developing the LOCOcyte™ Immunotherapy platform for the precision administration of potent immune effector molecules to treat solid tumors, today announced the successful completion of the first dose cohort in a Phase 1/2 clinical trial of AVB-001 in patients with refractory ovarian cancer.

Key Points: 
  • and QUINCY, Mass., April 26, 2023 /PRNewswire/ -- Avenge Bio, Inc. ("Avenge"), a clinical stage, oncology-focused biotechnology company developing the LOCOcyte™ Immunotherapy platform for the precision administration of potent immune effector molecules to treat solid tumors, today announced the successful completion of the first dose cohort in a Phase 1/2 clinical trial of AVB-001 in patients with refractory ovarian cancer.
  • The dose escalation trial evaluates the safety and tolerability, as well as preliminary efficacy, of AVB-001 administered intraperitoneally across a series of ascending dose-level cohorts.
  • "We are pleased to complete the first dose cohort in this Phase 1/2 clinical trial.
  • Although early, we are encouraged by the initial observations in this first dose level indicating the potential for this allogeneic cell-based immunotherapy.

Levy Konigsberg Files Motion to Consolidate 22 Talc Mesothelioma Lawsuits for Trial Against Johnson & Johnson

Retrieved on: 
Tuesday, April 25, 2023

NEW YORK, April 24, 2023 /PRNewswire/ -- Levy Konigsberg, a leading national law firm representing victims of corporate misconduct, has filed a motion to consolidate for trial the cases of 22 people diagnosed with mesothelioma caused by asbestos in Johnson's Baby Powder. The motion was filed in the Superior Court in Middlesex County, New Jersey, and seeks to have a jury evaluate the evidence of Johnson & Johnson's (J&J) egregious corporate wrongdoing.

Key Points: 
  • Levy Konigsberg files motion in New Jersey state court to consolidate for trial 22 mesothelioma cases caused by asbestos in Johnson's Baby Powder.
  • NEW YORK, April 24, 2023 /PRNewswire/ -- Levy Konigsberg, a leading national law firm representing victims of corporate misconduct, has filed a motion to consolidate for trial the cases of 22 people diagnosed with mesothelioma caused by asbestos in Johnson's Baby Powder.
  • The ruling allows these 22 mesothelioma cases, and other filed against J&J, to proceed toward long-awaited jury trials.
  • Levy Konigsberg LLP has been representing victims of mesothelioma in civil lawsuits since 1985.

Tango Therapeutics Presents Preclinical Data on Precision Oncology Programs at the American Association of Cancer Research 2023 Annual Meeting

Retrieved on: 
Tuesday, April 18, 2023

BOSTON, April 18, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX) today announced highlights from presentations at the American Association for Cancer Research (AACR) 2023 Annual Meeting, taking place from April 14-19, 2023 in Orlando, Florida.

Key Points: 
  • BOSTON, April 18, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX) today announced highlights from presentations at the American Association for Cancer Research (AACR) 2023 Annual Meeting, taking place from April 14-19, 2023 in Orlando, Florida.
  • “At this year’s AACR Annual Meeting, we presented preclinical data from four programs across our precision oncology portfolio, including two oral presentations.
  • It’s a tremendously exciting time for the field of precision oncology as we and others move into evaluating novel and previously not addressable targets.
  • TNG908 is 15X selective for MTAP-null cancer cells with the potential for broad clinical activity and a large therapeutic index.

ONCOTELIC PROVIDES YE 2022 FINANCIAL RESULTS COMPARED TO YE 2021 PRODUCT DEVELOPMENT INITIATIVES AND CORPORATE UPDATE

Retrieved on: 
Monday, April 17, 2023

In 2022 and continuing in the first quarter of 2023, the Company has made significant progress in various areas.

Key Points: 
  • In 2022 and continuing in the first quarter of 2023, the Company has made significant progress in various areas.
  • The Company also attended and participated in over ten different conferences and events during 2022 and made presentations at several.
  • The Company was also awarded funding from the Biomedical Advanced Research and Development Authority (“BARDA”) for the development of OT-101 for long COVID-19.
  • Highlights post close of FYE 2022:
    “FY 2022 was a challenging yet exciting year for all of us at Oncotelic,” said Amit Shah, CFO of Oncotelic.

Ikena Oncology Shares Differentiation Profile of IK-930, a Novel Hippo-Pathway Inhibitor, Including Projected Therapeutic Index Advantages and Breadth of Patient Populations at AACR 2023 Annual Meeting

Retrieved on: 
Monday, April 17, 2023

BOSTON, April 17, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that it will present preclinical data in two poster presentations highlighting the Company’s novel Hippo pathway inhibitor, IK-930, at the American Association for Cancer Research (AACR) Annual Meeting taking place in Orlando, FL from April 14-19, 2023.

Key Points: 
  • Data being shared today reveals that IK-930 selectively binds and inhibits TEAD1 and further describes the mechanism for its antitumor activity.
  • Key advantages demonstrated in the nonclinical studies include IK-930’s superior tolerability and comparable antitumor activity compared to panTEAD inhibition, resulting in a significantly improved projected therapeutic window in cancer patients.
  • IK-930 was designed as a TEAD1-selective inhibitor to avoid on-target renal toxicity expected from panTEAD inhibition.
  • TEAD1 is the most highly expressed TEAD paralog in mesothelioma and epithelioid hemangioendothelioma (EHE).

Sporos BioDiscovery Presents Preclinical Data on Next-Generation TEAD Inhibitor, SPR1-0117, at the American Association for Cancer Research (AACR) Annual Meeting 2023

Retrieved on: 
Monday, April 17, 2023

“Sporos” or the “Company”), a precision oncology company developing a diversified pipeline of small molecule therapeutic candidates, presented preclinical data for its lead candidate, SPR1-0117, a next-generation TEAD inhibitor at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.

Key Points: 
  • “Sporos” or the “Company”), a precision oncology company developing a diversified pipeline of small molecule therapeutic candidates, presented preclinical data for its lead candidate, SPR1-0117, a next-generation TEAD inhibitor at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.
  • SPR1-0117 targets cancers driven by mutations in the Hippo pathway, a key regulator of cell proliferation and oncogenesis not yet extensively targeted in precision oncology.
  • The YAP1/TAZ co-activators and the TEAD family of transcription factors, which consists of four paralogs (TEAD1-4), execute the pro-cancerous effects of the Hippo pathway through transcription of pro-proliferative and anti-apoptotic genes.
  • The published poster is now available in the News & Events section of the Sporos Bioventures website.

Precigen Presents Preclinical Data for the Next Generation Mesothelin UltraCAR-T® with Intrinsic PD-1 Blockade at the AACR Annual Meeting 2023

Retrieved on: 
Monday, April 17, 2023

GERMANTOWN, Md., April 17, 2023 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today presents preclinical data for the next generation UltraCAR-T platform utilizing MSLN CAR from Precigen's library of non-viral plasmids at the American Association for Cancer Research (AACR) Annual Meeting 2023. The abstract titled, "Next Generation UltraCAR-T® Cells with Intrinsic Checkpoint Inhibition and Overnight Manufacturing Overcome Suppressive Tumor Microenvironment Leading to Sustained Antitumor Activity" will be presented as a poster presentation on Monday, April 17, 2023 from 9:00 AM to 12:30 PM ET (Abstract #1791).

Key Points: 
  • Next generation MSLN UltraCAR-T cells were successfully engineered using a single multicistronic non-viral transposon and overnight manufacturing process to simultaneously express a CAR, mbIL15, a kill switch, and a novel mechanism for intrinsic PD-1 blockade.
  • Next generation MSLN UltraCAR-T cells exhibited markedly enhanced polyfunctionality as well as enhanced inflammatory cytokine production in the presence of MSLN+ PD-L1+ tumor cells.
  • "MSLN is the second target for the next generation UltraCAR-T incorporating intrinsic checkpoint inhibition, following our recently initiated Phase 1/1b study for PRGN-3007.
  • Precigen operates as an innovation engine progressing a preclinical and clinical pipeline of well-differentiated therapies toward clinical proof-of-concept and commercialization.

Researchers Report Clinical Proof-of-Concept Data for Vivace Therapeutics' VT3989, a First for a Cancer Drug Targeting the Hippo Pathway, in Oral Presentation at AACR 2023

Retrieved on: 
Sunday, April 16, 2023

SAN MATEO, Calif., April 16, 2023 /PRNewswire/ -- Vivace Therapeutics, Inc., a small molecule discovery and development company developing first-in-class therapies targeting the Hippo pathway, today announced that the first clinical data for a cancer treatment targeting the Hippo pathway was presented at the American Association for Cancer Research (AACR) Annual Meeting 2023. Results from the company's Phase 1 clinical study of its first-in-class transcriptional enhanced associate domain (TEAD) autopalmitoylation inhibitor, VT3989, showed the compound to be well tolerated with durable antitumor responses in patients with advanced malignant mesothelioma and other tumors with neurofibromatosis 2 (NF2) mutations. These findings were presented by Timothy A. Yap, M.D., Ph.D., of The University of Texas MD Anderson Cancer Center, during an oral plenary session at the conference. The AACR conference is being held April 14-19, 2023, in Orlando, Florida.

Key Points: 
  • The AACR conference is being held April 14-19, 2023, in Orlando, Florida.
  • Tumor response was observed in patients with mesothelioma with and without NF2 mutations and other solid tumors with NF2 mutations.
  • Because mesothelioma patients often have NF2 mutations or loss of Merlin it was an a priori indication of interest.
  • "Preclinical data suggested that blocking the YAP-TEAD interaction could shrink tumors, and these clinical data validate that approach.

Enochian BioSciences’ CEO Letter to Shareholders

Retrieved on: 
Monday, April 3, 2023

The fact that we saw very similar highly statistically significant results across two independently conducted studies is particularly encouraging, indicating reproducibility of the findings.

Key Points: 
  • The fact that we saw very similar highly statistically significant results across two independently conducted studies is particularly encouraging, indicating reproducibility of the findings.
  • I am pleased to be able to provide shareholders with a summary of recent advances and what we believe is a promising future for the Company.
  • This was accomplished while substantially reducing operating costs – including, at my request, a decrease in my compensation as CEO - towards maximizing shareholder value.
  • We look forward to your continued support as we work towards life-saving scientific advances and a promising new future for the Company.

Beasley Allen/Ashcraft & Gerel Law Firms: Talc MDL Leadership Rejects Johnson & Johnson’s Second Attempt to Abuse Bankruptcy Process

Retrieved on: 
Thursday, April 6, 2023

This week, Johnson & Johnson announced what the company says is a resolution of tens of thousands of talc ovarian cancer and mesothelioma claims.

Key Points: 
  • This week, Johnson & Johnson announced what the company says is a resolution of tens of thousands of talc ovarian cancer and mesothelioma claims.
  • There are no tactics too underhanded for the company to use to try to avoid paying reasonable compensation to these cancer victims.
  • The talc “settlement” being touted by J&J and the media is NOT a settlement.
  • It is an illusory proposal for a bankruptcy plan, yet another attempt by J&J to misuse the bankruptcy system.